MarketScreener Homepage > Equities > Swiss Exchange > Roche Holding AG ROG CH0012032048

Report

Delayed Swiss Exchange - 01/22 11:30:30 am
318.45	CHF		+0.54%

01/22

ROCHE HOLDINGS AG : Barclays reiterates its Buy rating

01/21

ROCHE : Genentech's Esbriet Gets FDA Priority Review in Unclassifiable Interstitial Lung Disease

01/21

ROCHE : US FDA Accepts Roche's Lung Disease Therapy Esbriet For New Drug Review

News

Press Releases

Official Publications

Sector news

MarketScreener Strategies

Communiqués de presse de la société ROCHE HOLDING AG

01/21	ROCHE : FDA grants priority review to Roche's Esbriet (pirfenidone) for unclassi..	PU
01/21	ROCHE : FDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Uncl..	BU
01/19	CHUGAI PHARMACEUTICAL : Supports the Japan Climate Initiative's Calling to Raise..	AQ
01/18	ROCHE ANNUAL GENERAL MEETING 2021 : Exercising of shareholder rights via the ind..	AQ
01/13	CHUGAI PHARMACEUTICAL : Conducts Digital Transformation in Manufacturing with IB..	AQ
01/12	ROCHE : confirms US government agreement to purchase additional doses of Regener..	AQ
01/12	ROCHE : CHEPLAPHARM acquires the rights to Rivotril	AQ
01/12	ROCHE : to present updated data confirming Tecentriq in combination with Avastin..	AQ
01/11	ROCHE : Xofluza approved by the European Commission for the treatment of influen..	AQ
01/11	ROCHE : launches two digital pathology image analysis algorithms for precision p..	AQ
01/11	ROCHE : Xofluza approved by the European Commission for the treatment of influen..	AQ
01/05	ROCHE : Invitation to Roche's Full Year Results 2020 Presentation	PU
01/05	GENENTECH : 's Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Des..	BU
01/05	ROCHE : novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designatio..	AQ
2020	Chugai Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic ..	AQ
2020	HALOZYME THERAPEUTICS : Announces Roche Receives European Commission Approval fo..	AQ
2020	CHUGAI PHARMACEUTICAL THE : Launch of Chugai's New TV Commercial Featuring Erika..	AQ
2020	ROCHE : European Commission approves Roche's Phesgo (fixed-dose combination of P..	AQ
2020	CHUGAI PHARMACEUTICAL : Osteoporosis Agent Edirol Obtains Regulatory Approval in..	AQ
2020	ROCHE : faricimab meets primary endpoint and shows strong durability across two ..	AQ
2020	GENENTECH : 's Faricimab Meets Primary Endpoint and Shows Strong Durability Acro..	BU
2020	REGENERON PHARMACEUTICALS : New England Journal of Medicine Publishes Positive I..	AQ
2020	ROCHE : Diagnostics to create Software Development Hub in Laval, Quebec	AQ
2020	ROCHE : FDA Approves Genentech's Ocrevus Shorter 2-Hour Infusion for Relapsing a..	AQ
2020	ROCHE : launches cobas PIK3CA Mutation Test for patients with advanced or metast..	AQ
2020	ROCHE : FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for ..	AQ
2020	ROCHE : FDA Approves Genentech's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion f..	BU
2020	CHUGAI PHARMACEUTICAL : in-licenses Antibody Cocktail for COVID-19 from Roche	AQ
2020	ROCHE : launches laboratory SARS-CoV-2 antigen test to support high-volume testi..	AQ
2020	ROCHE : presents exploratory data from the Phase III IMvigor010 study in early b..	AQ
2020	ROCHE : UC Davis - The next generation of combined COVID-19 and flu test rolls o..	AQ
2020	CURIS : Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-494..	AQ
2020	ROCHE : New Roche antibody test to be used in Moderna COVID-19 vaccine trial	AQ
2020	ROCHE : partners with Moderna to include SARS-CoV-2 antibody test in ongoing COV..	AQ
2020	ROCHE : New follow-up phase III data reinforce the long-term benefit of Roche's ..	AQ
2020	CURIS : Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948..	AQ
2020	ROCHE : presents new data from its bispecific antibody portfolio across a range ..	AQ
2020	ROCHE : announces new data reinforcing the long-term benefit of Venclexta/Vencly..	AQ
2020	ROCHE : New data presented at ASH 2020 reinforces the benefit/risk profile of fi..	AQ
2020	ROCHE : New follow-up phase III data reinforce the long-term benefit of Roche's ..	AQ
2020	ROCHE : announces new data reinforcing the long-term benefit of Venclexta/Vencly..	AQ
2020	GENENTECH : Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Ba..	BU
2020	ROCHE : Genentech Announces FDA Approval of Gavreto for People With Advanced or ..	AQ
2020	ROCHE : announces FDA approval of Gavreto (pralsetinib) for people with advanced..	AQ
2020	ROCHE : receives FDA Emergency Use Authorization for new test to measure the lev..	AQ
2020	GENENTECH : Announces FDA Approval of Gavreto (pralsetinib) for People With Adva..	BU
2020	ROCHE : FDA approves Xolair® (omalizumab) for adults with nasal polyps	AQ
2020	GENENTECH : Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal ..	BU
2020	REMINDER : Invitation to Roche's virtual event on key hematology data presented ..	PU
2020	Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules	AQ
2020	Chugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease A..	AQ
2020	SHIONOGI : Announces FDA Approval of XOFLUZA for the prevention of Influenza fol..	AQ
2020	ROCHE : Genentech Announces FDA Approval of Xofluza for the Prevention of Influe..	AQ
2020	ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..	PU
2020	ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..	PU
2020	ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..	AQ
2020	GENENTECH : Announces FDA Approval of Xofluza for the Prevention of Influenza Fo..	BU
2020	ROCHE : Regeneron's REGN-COV2 is first antibody cocktail for COVID-19 to receive..	PU
2020	CHUGAI PHARMACEUTICAL : Receives the Best IR Award	AQ
2020	CHUGAI PHARMACEUTICAL : Selected for the First Time in the 'DJSI World,' a Globa..	AQ
2020	DICERNA PHARMACEUTICALS : Announces Positive Updated Data from Phase 1 Trial of ..	AQ
2020	SPARK THERAPEUTICS : Expands Visionary Leadership with Appointment of Michael Re..	AQ
2020	ROCHE : Leading Diagnostics Companies Join Forces to Establish the Access to Com..	PR
2020	ROCHE : CHMP recommends EU approval of Roche's Xofluza for the treatment of infl..	AQ
2020	HALOZYME THERAPEUTICS : Announces CHMP Recommends EU Approval of Roche's Phesgo ..	AQ
2020	ROCHE : Spark Therapeutics Expands Visionary Leadership with Appointment of Mich..	AQ
2020	ROCHE : CHMP recommends EU approval of Roche's Xofluza® (baloxavir marboxil) for..	AQ
2020	ROCHE : ranked the most sustainable healthcare company in the Dow Jones Sustaina..	AQ
2020	ROCHE : CHMP recommends EU approval of Roche's Xofluza® (baloxavir marboxil) for..	PU
2020	ROCHE : CHMP recommends EU approval of Roche's Xofluza® (baloxavir marboxil) for..	AQ
2020	ROCHE : UC Davis - New cutting-edge rapid test detects both COVID-19 and flu	AQ
2020	ROCHE : CHMP recommends EU approval of Roche's Phesgo (fixed-dose combination of..	PU
2020	ROCHE : CHMP recommends EU approval of Roche's Phesgo (fixed-dose combination of..	AQ
2020	CURIS : Reports Third Quarter 2020 Financial Results	AQ
2020	CURIS : Announces Collaboration with the National Cancer Institute for the Devel..	AQ

1 2 3 4 5 6 7 8 9 10 Next

Analysis

AstraZeneca shares fall on 'hefty' $39-billion Alexion deal